{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T01:10:10Z","timestamp":1744938610733,"version":"3.40.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,17]]},"DOI":"10.7759\/cureus.82471","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:42:06Z","timestamp":1744936926000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Daily Teriparatide in Managing Glucocorticoid-Induced Osteoporosis in Rheumatic Disease Patients After Switching From Bisphosphonate Therapy"],"prefix":"10.7759","author":[{"given":"Kaichi","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kaburaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Shikano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman JM","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK, et al.. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010, 62:1515-26. 10.1002\/acr.20295","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-004-0596-x","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004)","volume":"23","author":"Nawata H","year":"2005","unstructured":"Nawata H, Soen S, Takayanagi R, et al.. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005, 23:105-9. 10.1007\/s00774-004-0596-x","journal-title":"J Bone Miner Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"61","author":"Compston J","year":"2018","unstructured":"Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018, 61:7-16. 10.1007\/s12020-018-1588-2","journal-title":"Endocrine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez A","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D, et al.. Treatment failure in osteoporosis. Osteoporos Int. 2012, 23:2769-74. 10.1007\/s00198-012-2093-8","journal-title":"Osteoporos Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman AB","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, et al.. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005, 26:688-703. 10.1210\/er.2004-0006","journal-title":"Endocr Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll ES","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, et al.. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003, 18:9-17. 10.1359\/jbmr.2003.18.1.9","journal-title":"J Bone Miner Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body JJ","year":"2002","unstructured":"Body JJ, Gaich GA, Scheele WH, et al.. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002, 87:4528-35. 10.1210\/jc.2002-020334","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010292","article-title":"Improvement in glucocorticoid-induced osteoporosis on switching from bisphosphonates to once-weekly teriparatide: a randomized open-label trial","volume":"12","author":"Nanki T","year":"2022","unstructured":"Nanki T, Kawazoe M, Uno K, et al.. Improvement in glucocorticoid-induced osteoporosis on switching from bisphosphonates to once-weekly teriparatide: a randomized open-label trial. J Clin Med. 2022, 12:10.3390\/jcm12010292","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-019-0111-3","article-title":"RANKL biology: bone metabolism, the immune system, and beyond","volume":"40","author":"Ono T","year":"2020","unstructured":"Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020, 40:2. 10.1186\/s41232-019-0111-3","journal-title":"Inflamm Regen"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070028","article-title":"Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption","volume":"11","author":"Aubin JE","year":"2000","unstructured":"Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2000, 11:905-13. 10.1007\/s001980070028","journal-title":"Osteoporos Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0794","article-title":"Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment","volume":"90","author":"Rogers A","year":"2005","unstructured":"Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005, 90:6323-31. 10.1210\/jc.2005-0794","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1971","article-title":"Changes of serum soluble receptor activator for nuclear factor-\u03baB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts","volume":"97","author":"Kaneko K","year":"2012","unstructured":"Kaneko K, Kusunoki N, Hasunuma T, Kawai S. Changes of serum soluble receptor activator for nuclear factor-\u03baB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts. J Clin Endocrinol Metab. 2012, 97:E1909-17. 10.1210\/jc.2012-1971","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis : report of a WHO study group [\u200emeeting held in Rome from 22 to 25 June 1992]\u200e","author":"World Health Organization","year":"1994","unstructured":"World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis : report of a WHO study group [\u200emeeting held in Rome from 22 to 25 June 1992]\u200e. World Health Organization, Geneva, Switzerland; 1994."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346537","article-title":"New perspectives on the definition and the management of severe osteoporosis: the patient with two or more fragility fractures","volume":"32","author":"Nuti R","year":"2009","unstructured":"Nuti R, Brandi ML, Isaia G, Tarantino U, Silvestri S, Adami S. New perspectives on the definition and the management of severe osteoporosis: the patient with two or more fragility fractures. J Endocrinol Invest. 2009, 32:783-8. 10.1007\/BF03346537","journal-title":"J Endocrinol Invest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/a-2015-1747","article-title":"Comparison of bisphosphonates versus teriparatide in therapy of the glucocorticoid-induced osteoporosis (GIOP): a meta-analysis of randomized controlled trials","volume":"55","author":"Dong B","year":"2023","unstructured":"Dong B, Zhou Y, Wang J, et al.. Comparison of bisphosphonates versus teriparatide in therapy of the glucocorticoid-induced osteoporosis (GIOP): a meta-analysis of randomized controlled trials. Horm Metab Res. 2023, 55:236-44. 10.1055\/a-2015-1747","journal-title":"Horm Metab Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100293","article-title":"Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment","volume":"13","author":"Hirooka Y","year":"2020","unstructured":"Hirooka Y, Nozaki Y, Inoue A, et al.. Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Bone Rep. 2020, 13:100293. 10.1016\/j.bonr.2020.100293","journal-title":"Bone Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce BF","year":"2008","unstructured":"Boyce BF, Xing L. Functions of RANKL\/RANK\/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008, 473:139-46. 10.1016\/j.abb.2008.03.018","journal-title":"Arch Biochem Biophys"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.12659\/msm.903432","article-title":"Parathyroid hormone (PTH) induces autophagy to protect osteocyte cell survival from dexamethasone damage","volume":"23","author":"Zhu L","year":"2017","unstructured":"Zhu L, Chen J, Zhang J, Guo C, Fan W, Wang YM, Yan Z. Parathyroid hormone (PTH) induces autophagy to protect osteocyte cell survival from dexamethasone damage. Med Sci Monit. 2017, 23:4034-40. 10.12659\/msm.903432","journal-title":"Med Sci Monit"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag KG","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, et al.. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009, 60:3346-55. 10.1002\/art.24879","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag KG","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, et al.. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007, 357:2028-39. 10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.12.021","article-title":"Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate","volume":"46","author":"Eastell R","year":"2010","unstructured":"Eastell R, Chen P, Saag KG, Burshell AL, Wong M, Warner MR, Krege JH. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone. 2010, 46:929-34. 10.1016\/j.bone.2009.12.021","journal-title":"Bone"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07386-4","article-title":"Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study","volume":"36","author":"Yukishima T","year":"2025","unstructured":"Yukishima T, Ebina K, Etani Y, et al.. Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study. Osteoporos Int. 2025, 36:531-8. 10.1007\/s00198-025-07386-4","journal-title":"Osteoporos Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae810","article-title":"Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy","author":"Kawazoe M","year":"2024","unstructured":"Kawazoe M, Kaneko K, Masuoka S, et al.. Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy. J Clin Endocrinol Metab. 2024, 10.1210\/clinem\/dgae810","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/347281-effectiveness-of-daily-teriparatide-in-managing-glucocorticoid-induced-osteoporosis-in-rheumatic-disease-patients-after-switching-from-bisphosphonate-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:42:06Z","timestamp":1744936926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/347281-effectiveness-of-daily-teriparatide-in-managing-glucocorticoid-induced-osteoporosis-in-rheumatic-disease-patients-after-switching-from-bisphosphonate-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.82471","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}